Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Apr 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-03-31

Reporting Person: Islam Khalid (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-31	Common Stock	A	4392	—	Acquired	72486	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	120909	Indirect

Footnotes

F1: Vesting of time-based restricted shares.

F2: Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in a transaction exempt from Section 16 reporting pursuant to Rule 16a-13.